Obesity-fighting drugs may reduce alcohol consumption in individuals with alcohol use disorder
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalisations among individuals with alcohol use disorder, AUD. Fewer hospitalisations were observed for alcohol related causes, substance use related causes, and for physical illnesses. However, no association was observed for hospitalisations due to attempted suicide. Effective treatments for alcohol dependence exist; however, they remain underused and are not